Theravance Biopharma (TBPH) Projected to Post Earnings on Wednesday

Theravance Biopharma (NASDAQ:TBPH) will likely be posting its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Theravance Biopharma to post earnings of $0.44 per share and revenue of $43.0870 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 2, 2026 at 4:00 PM ET.

Theravance Biopharma Stock Performance

Shares of TBPH stock opened at $19.66 on Monday. Theravance Biopharma has a fifty-two week low of $7.90 and a fifty-two week high of $21.03. The firm has a market capitalization of $996.17 million, a price-to-earnings ratio of 34.49 and a beta of 0.15. The stock’s 50-day simple moving average is $19.28 and its 200-day simple moving average is $16.58.

Insider Buying and Selling at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total value of $582,506.25. Following the completion of the transaction, the senior vice president directly owned 277,695 shares in the company, valued at $5,206,781.25. The trade was a 10.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 6.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Theravance Biopharma

Several hedge funds have recently modified their holdings of TBPH. Arrowstreet Capital Limited Partnership purchased a new position in shares of Theravance Biopharma in the 3rd quarter valued at about $10,611,000. Janus Henderson Group PLC grew its holdings in Theravance Biopharma by 214.8% in the fourth quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock valued at $7,493,000 after purchasing an additional 273,288 shares during the period. Two Sigma Investments LP grew its holdings in Theravance Biopharma by 1,199.9% in the third quarter. Two Sigma Investments LP now owns 231,272 shares of the biopharmaceutical company’s stock valued at $3,377,000 after purchasing an additional 213,480 shares during the period. HRT Financial LP increased its position in shares of Theravance Biopharma by 892.8% in the fourth quarter. HRT Financial LP now owns 232,852 shares of the biopharmaceutical company’s stock valued at $4,356,000 after buying an additional 209,397 shares in the last quarter. Finally, Rock Springs Capital Management LP acquired a new position in shares of Theravance Biopharma during the 4th quarter worth approximately $3,906,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on TBPH shares. HC Wainwright upped their price target on shares of Theravance Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. Wall Street Zen lowered Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. BTIG Research reaffirmed a “buy” rating and set a $40.00 price target on shares of Theravance Biopharma in a research report on Tuesday, February 3rd. Finally, Oppenheimer began coverage on Theravance Biopharma in a report on Wednesday, December 3rd. They issued an “outperform” rating and a $27.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Theravance Biopharma presently has a consensus rating of “Buy” and an average price target of $27.80.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.